This application by the Ann Arbor Regional CCOP (a component of the Catherine McAuley Cancer Center in Ann Arbor, Michigan) meets and exceeds the performance requirements of an NCI funded CCOP. The investigators are experienced members currently involved in CCOP activities as a satellite of another CCOP, based in Toledo, Ohio. However, the research program of the Ann Arbor CCOP has matured significantly over the past 6 years and this past year the investigators entered 125 patients on clinical and cancer control trials. Further, the Ann Arbor Regional CCOP and the Center have a strong interest in developing cancer control initiatives, an activity that is difficult to accomplish if the program is not a fully funded CCOP. Over the past year, the Ann Arbor CCOP has developed credibility with its research bases as a group capable of significant accrual, high quality data management and an interest in participating in the science of the research base. For example, Dr. Philip Stella, our Principal Investigator, is currently Principal Investigator of an NCCTG protocol. Dr. Miljenko Pilepich, our Co-Investigator has a national reputation in radiation oncology, with significant national credentials and participation. This proposal has the firm commitment of the Center to fund several of the key staff, and the strong support by all of the oncologists and a broad cross section of the St. Joseph Mercy Hospital medical staff. The Cancer Center staff is experienced and has already been evaluated as part of an existing CCOP.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA063848-05
Application #
2712698
Study Section
Special Emphasis Panel (ZCA1-RLB-7 (J2))
Program Officer
Parnes, Howard L
Project Start
1994-08-05
Project End
2002-05-31
Budget Start
1998-06-01
Budget End
1999-05-31
Support Year
5
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Catherine Mc Auley Health Center
Department
Type
DUNS #
City
Ann Arbor
State
MI
Country
United States
Zip Code
48106
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Lubner, Sam; Feng, Yang; Mulcahy, Mary et al. (2018) E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors. Oncologist 23:1006-e104
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Hubbard, Joleen M; Mahoney, Michelle R; Loui, William S et al. (2017) Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Target Oncol 12:201-209
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ? 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Crozier, Jennifer A; Advani, Pooja P; LaPlant, Betsy et al. (2016) N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy. Clin Breast Cancer 16:23-30
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068

Showing the most recent 10 out of 153 publications